What do systematic reviews say?

Neoadjuvant treatment vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant treatment changes overall survival (OS), measured by the number of deaths over time… compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.43 [0.15, 1.21]
  2 studies · 171 participants
  Very low

Neoadjuvant treatment vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant treatment changes adverse events, compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  RR 1.58
  2 studies · 162 participants
  Very low

Neoadjuvant treatment vs no neoadjuvant treatment

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant treatment vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant treatment changes time to recurrence (TTR),measured by the number of disease… compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.51 [0.22, 1.17]
  2 studies · 171 participants
  Very low

Neoadjuvant treatment vs no neoadjuvant treatment

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant targeted treatment (BRAF/MEK inhibition) changes overall survival (OS), measured by number of deaths over time,Median compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.28 [0.03, 2.25]
  1 study · 21 participants
  Very low

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 14 participants
  Low

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 13 participants
  Low

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant targeted treatment (BRAF/MEK inhibition) changes time to recurrence (TTR), measured by the number of disease… compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.02 [0, 0.22]
  1 study · 21 participants
  Very low

Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy

It is very uncertain whether neoadjuvant immunotherapy (high dose interferon) plus chemotherapy changes overall response rate (ORR), measured after 8 weeks of treatment and… compared with neoadjuvant chemotherapy (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  RR 1.75 [0.62, 4.95]
  1 study · 36 participants
  Very low

Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes overall survival (OS), measured by the number of deaths over time, compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.49 [0.15, 1.64]
  1 study · 150 participants
  Very low

Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes adverse Events, compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  RR 2.84 [0.96, 8.37]
  1 study · 142 participants
  Very low

Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Very low

Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes time to recurrence (TTR), measured by the number of disease… compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.75 [0.31, 1.79]
  1 study · 150 participants
  Very low

Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 86 participants
  Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in overall response rate (ORR), compared with neoadjuvant immunotherapy (sequential treatment with ipilimumab then… (low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  RR 1.42 [0.87, 2.32]
  1 study · 86 participants
  Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found